Login / Signup

Effect of DNMT3A R882H Hot Spot Mutations on DDX43 Promoter Methylation in Acute Myeloid Leukemia.

Tahere TabatabaeiMohammad Reza RezvanyBahare GhasemiFarzane VafaeiMasoumeh Kiani ZadehFarhad ZakerArash Salmaninejad
Published in: BioMed research international (2024)
Epigenetic alterations have been observed in many hematological malignancies, including acute myeloid leukemia (AML). Many of these alterations result from mutations in DNA methyl transferase (DNMT) enzymes, disabling them to methylate target genes in a proper way. In this case-control study, we investigated the association between R882H mutation in DNMT3A gene and DDX43 gene methylation in patients with AML. 47 AML patients and 6 controls were included in this study. After DNA extraction, amplification refractory mutation system (ARMS)-PCR was used to evaluate R882H mutations in DNMT3A gene. The high-resolution melting (HRM) method was used to determine the methylation changes of the DDX43 gene promoter. R882H mutation was only found in 10.6% (5 out of 47) of AML patients. The frequency of DDX43 gene methylation was significantly higher in patients without R882H mutations compared to patients with R882H mutations ( P < 0.05). The DNMT3A R882H mutation is typically present in a minority of AML patients. Nevertheless, this mutation is associated with a reduced frequency of methylation in the DDX43 promoter region.
Keyphrases
  • dna methylation
  • acute myeloid leukemia
  • genome wide
  • end stage renal disease
  • ejection fraction
  • high resolution
  • newly diagnosed
  • chronic kidney disease
  • gene expression
  • prognostic factors
  • peritoneal dialysis